Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2022
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Development of iPSC-derived Disease Models
Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires
Lab-grown meat is fast becoming a real alternative to its farm-grown counterpart as billionaire entrepreneurs and industry heavyweights invest into start-ups from across the nascent field of “cellular agriculture”. Produced via stem cells derived from cows, pigs, fish, sheep, or other livestock, the emerging clean meat industry has the potential to transform the global food market and create a new trillion dollar industry in the process. [Read more…]
Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market
In July of 2018, Takara Bio 
announced that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, had granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells were to be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.
This announcement made Takara Bio the first company worldwide to offer this service for human ESCs.
Takara Bio’s Role with Human Pluripotent Stem Cells
The significance of this event is that Takara Bio is capable of providing a predictable and reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities, according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]
- 1
- 2
- 3
- …
- 8
- Next Page »
